The clinical proof of concept and potential of cell engager drugs has led to investments and collaborations exploding in the field of multi-specific cell engaging antibody drugs.
The exclusive, digital Cell Engager Summit will address the key challenges hindering multi-specific cell engaging drugs from fulfilling their potential and becoming a mainstream cancer therapy.
Join industry leaders to:
Assess current limitations of cell engagers to mitigate toxicities and ensure patient safety
Address Half-Life and Cytokine Release Syndrome to Improve the Therapeutic Window: Explore bivalent target engagement and combination therapies
Learn what drugs are currently in pre-clinical and clinical stages of development: Novel clinical data outlining study designs for liquid and solid tumors
Compare the biology of T-cells, NK cells and Gamma Delta cells for use in immune-oncology: Learn from case studies about the advantages and disadvantages of each cell type
Analyze tumor target selection to maximize efficacy whilst minimizing toxicity: Compare platforms, target feasibility and selection
Optimize the next generation of cell engager drug discovery: Through advances in technology to achieve maximum therapeutic response
Compare Cell Engager therapeutics with CAR-T and Bispecifics: Comparing design strategies and benchmarking T Cell-Redirecting Therapies